SIOP COVID-19 Resource: https://siop-online.org/covid-19-resources-and-guidance/
SIOP has established a page that lists in one place COVID-19 resources of targeted interest to the pediatric/adolescent oncology community. This list is curated through the submission from the medical community (see below to contribute).
- Guidance documents from academic research groups (e.g., CCLG, COG, St. Jude’s)
- Guidance documents from health organizations such as WHO (updated daily), PAHO, ASCO, WSPID, ESMO, Royal College,
- Peer reviewed publications
COVID-19 Resources Submission Form
“It is becoming clear that children and adolescents living with cancer and older people are particularly vulnerable to COVID-19, and that health systems in rich and poor countries alike are ill-equipped to respond.
In light of the above, we would be interested in learning how our members are rising to challenges posed by the pandemic. Please don’t hesitate to use this form to share any relevant information, insight and resources with us which we can post under our resource collection above.
SIOP reserves the right to select resources and cannot guarantee the inclusion of a resource shared. While we will endeavour to keep the list up to date, we rely on you to let us know any updates to the resources using this form.
The subsequent resource is for supporting the wider community on issues relating to paediatric and adolescent cancer and COVID-19. At this point, it is not for promotion of particular agendas or advocacy resources.”
CADTH Lecture The Canadian Partnership for Tomorrow Project | Conférences de l’ACMTS Le Projet de partenariat canadien Espoir pour demain [register for the 16-Jan-2020, livestream]
The Canadian Partnership for Tomorrow Project: Canada’s Population Health Cohort
Speaker: Dr. Philip Awadalla, PhD, National Scientific Director for the CPTP, Director of Computational Biology, and the Executive Scientific Director of the Ontario Health Study at the Ontario Institute for Cancer Research, and Professor of Population and Medical Genomics at the University of Toronto.
The Canadian Partnership for Tomorrow Project (CPTP) is Canada’s largest population cohort that allows researchers to explore how genetics, environment, lifestyle, and behaviour interact and contribute to the development of cancer and other chronic diseases. The national cohort brings together six regional cohorts: BC Generations Project, Alberta’s Tomorrow Project, the Manitoba Tomorrow Project, Ontario Health Study, CARTaGENE, and the Atlantic Partnership for Tomorrow’s Health. These cohorts have cumulatively enrolled more than 320,000 Canadians who are older than 30. Baseline data has been harmonized across the country, creating a pan-Canadian resource of more than 1,600 measures of participant health and lifestyle factors, including, but not limited to: personal and family disease histories, medication use, sex and reproductive health, diet and nutrition, sun exposure, and alcohol and tobacco use. More than 150,000 participants have provided biological samples, measures of glycated hemoglobin, complete blood counts, and physical measurements (e.g., anthropometrics, blood pressure, and body fat percentage). A significant benefit of CPTP is that all participants have provided consent to link their information to regional administrative health databases. This unique feature enables the longitudinal analyses of changes in clinical outcomes carried out in parallel with the analysis of biologics and deeply characterized health and lifestyle information. Alongside a wealth of cardiometabolic phenotypes, CPTP is well positioned to support studies focused on how genetics and the environment interact to drive cancer, cardiovascular disease, diabetes onset, and other outcomes in the Canadian context.
Date: Thursday, January 16, 2020, in person or via live stream
Time: 1:30 p.m. to 2:45 p.m. EST
Location: Dow’s Lake Court Conference Centre, 865 Carling Avenue, Ottawa, Ontario
Live stream: Details on registration
There is no fee to participate, but you must register by Wednesday January 15, 2020, to attend or livestream the event.
Feel free to distribute this invitation within your networks. We sincerely hope you and your colleagues can join us. If you have any questions about the lecture or how to register, please contact us at firstname.lastname@example.org.
Le Projet de partenariat Canadien Espoir pour demain : la santé de la population au Canada
Conférencière : Le Dr Philip Awadalla est le directeur scientifique national du Projet de partenariat canadien Espoir pour demain, le directeur de la bio-informatique et le directeur général scientifique de l’Étude sur la santé Ontario à l’Institut ontarien de recherche sur le cancer. De plus, il enseigne la génomique des populations et la génomique médicale à l’Université de Toronto et il dirige le Centre canadien d’intégration des données de Génome Canada. Il est titulaire d’un doctorat en génétique des populations et en génétique statistique de l’Université d’Édimbourg. Il poursuit des études postdoctorales grâce à des bourses d’études (NSERC, Killam, Wellcome Trust), puis il occupe un poste de professeur aux universités de la Caroline du Nord et de Montréal. Pendant un temps, il est le directeur scientifique de CARTaGENE et fait partie du groupe d’analyse du projet 1 000 Génomes et du Pan-Cancer Analysis of Whole Genomes. Ses principaux projets sont axés sur la génomique du vieillissement, les maladies hématologiques et le cancer. D’autres portent sur l’estimation des taux de mutation et de recombinaison, la modélisation et la génétique, et les risques environnementaux de maladies infectieuses en Afrique.
Le Projet de partenariat canadien Espoir pour demain (PPCED) représente la plus vaste plateforme de recherche sur la santé de la population au Canada; dans le cadre de ce projet, des chercheurs étudient l’influence et l’interaction de facteurs génétiques et environnementaux, du mode de vie et du comportement dans l’apparition du cancer et d’autres maladies chroniques. D’importance cruciale, le PPCED permettra de mieux comprendre l’interaction entre des facteurs individuels comme le style de vie, le comportement et la génétique et l’environnement, et leur influence dans l’apparition du cancer et d’autres maladies. La cohorte nationale regroupe six cohortes régionales : le projet BC Generations, le projet Tomorrow de l’Alberta, le projet Tomorrow du Manitoba, l’Étude sur la santé Ontario, le projet CARTaGENE et le projet LA VOIE Atlantique; elle compte plus de 320 000 Canadiennes et Canadiens de plus de 30 ans. Les données de base recueillies au pays ont été harmonisées et elles forment une ressource pancanadienne portant sur plus de 1 600 paramètres mesurés sur la santé et le mode de vie, dont les antécédents médicaux personnels et familiaux, les médicaments utilisés, le sexe et la santé reproductive, le régime alimentaire et la nutrition, l’exposition au soleil, la consommation d’alcool et le tabagisme. Plus de 150 000 participants ont offert des échantillons biologiques, des mesures du taux d’hémoglobine glyquée, des hémogrammes et des mesures physiques (p. ex., caractéristiques anthropométriques, pression artérielle, pourcentage de gras corporel). L’une des retombées importantes du projet est que tous les participants ont consenti à ce que leurs renseignements personnels soient versés dans des bases de données administratives régionales du secteur de la santé. Ainsi, il est possible d’analyser dans une perspective longitudinale l’évolution des résultats cliniques en parallèle avec l’analyse des échantillons biologiques et de l’information individuelle étoffée sur la santé et le mode de vie. Corpus d’une vaste gamme de phénotypes cardiométaboliques, le PPCED constitue également une mine de renseignements permettant l’étude de l’interaction entre les facteurs génétiques et environnementaux dans l’apparition du cancer, des maladies cardiovasculaires, du diabète et d’autres problèmes de santé au Canada.
Date : Jeudi 16 janvier 2020
Heure : 13 h 30 à 14 h 45
Lieu : Salle du conseil, Dow’s Lake Court, ou en diffusion continue en direct
La conférence est offerte gratuitement, mais il faut s’y inscrire au plus tard mercredi 16 janvier 2020.
Inscrivez-vous dès maintenant: https://cadth.ca/fr/evenements/le-projet-de-partenariat-canadien-espoir-pour-demain-la-sante-de-la-population-au-canada
N’hésitez pas à partager cette invitation au sein de votre réseau. Nous espérons sincèrement que vous-même et certains de vos collègues pourrez vous joindre à nous lors de cette conférence. Si vous avez des questions à ce sujet ou encore pour savoir comment vous inscrire, n’hésitez pas à nous contacter à email@example.com.
Pediatricians, Family Physicians, Pediatric Oncologists, Pediatric Hematologists & all healthcare professionals involved in pediatric cancer care or hematological disorders
The Provincial Pediatric Oncology Hematology Network, in conjunction with the Division of Pediatric Oncology Hematology BMT, BC Children’s Hospital, is committed to providing ongoing educational and discussion opportunities to support physicians and healthcare providers in the care of the child/adolescent with cancer and hematological disorders. This educational day has been developed to reflect the needs of these physicians and multidisciplinary healthcare professionals. There will be opportunity for dialogue, discussion, and Q&A throughout the program.
Thursday November 21
- 1800 Registration & Dinner
- 1900 The Private World of Dying Children | Pam Chace, Ilana Katz, Farah Valimohamed & Eric Webber
- 2030 Evening Ends
Friday November 22
0745 Registration & Breakfast
0830 Grand Grounds: Privacy Obligations in the Digital Age | Dennis Desai
0940 Welcome and Introduction | Elaine Peddie
1000 Life in the North │ Darlene Fjellgaard & Alice Christensen
1015 CAR-T Cells Explained │ Amanda Li
1055 Coffee Break
1115 What’s New in Neuroblastoma │ Rebecca Deyell
1150 Cannabis and Kids │ Rod Rassekh
1230 Networking Lunch (provided)
1330 Small Group Sessions
A) The ‘F’ Word: Safe Opioid Use│ Myles Cassidy & Randa Ridgway
B) Life with a Bleeding Disorder | Erica Crilly
C) Life after Cancer: The First Year | Meera Rayar
D) “Will I give it to him?”: Facts & Myths about Sexual Health in Adolescent Oncology | Emily Jewels
E) Gratitude as a Practice to Enhance Courage and Resilience in the Workplace | Janie Brown
1420 Travel to Next Session
1430 Repeat of Small Group Sessions
1520 Refreshment Break
1545 Motivational Parenting at the Bedside | Shimi Kang
1630 Closing Remarks & Completion of Evaluation Forms
1635 Tours of the Clinic | Analyn Perez
JOB POSTING: Part-time pediatric physician in Pediatric Hematology, Oncology & BMT at BCCH (open until filled)
Regular – Part Time Position (0.5-1.0 FTE)
Competition # HEM.16
Department of Pediatrics Division of Pediatric Hematology, Oncology & BMT
BC Children’s Hospital
Reporting to the Division Head of Hem/Onc/BMT, this Clinical Associate Physician position includes direct patient care in the inpatient and outpatient setting. Provision of care will be to both Pediatric Hematology and Oncology patients. Responsibilities include participation in team meetings, performing procedures, maintenance of patient health records, dictations, signing off on reports and physician orders in a timely manner and in accordance with the Division and C&W health record policies. As a key member of our multidisciplinary team, you will ensure a high level of
professional competence expected of a physician.
Applicants must have a Medical Degree and must be eligible for registration with the BC College of Physicians and Surgeons. Experience in Pediatrics or Pediatric Hematology/Oncology is considered an asset.
Candidates should possess excellent clinical skills with demonstrated ability to work effectively with patients and their families. Be able to demonstrate a strong commitment to best practice and advancing knowledge in this field of practice. Strong inter-professional skills in working in complex environments and commitment to a clinical academic sub-specialty environment will ensure your success in this role.
Qualified candidates should quote Competition Hem.16 submit their most current CV; covering letter and the name, title, rank and contact information of 4 referees to:
Dr. Caron Strahlendorf
Head, Division of Pediatric Hematology,
Oncology, and Bone Marrow Transplant.
Applications will be accepted until a suitable candidate is found.
Start Date: As soon as possible.
BC Children’s Hospital (BCCH) cares for the province’s most acutely ill or injured children and youth, provides developmental and rehabilitation services to children and youth throughout BC, and offers a broad range of health services. Sunny Hill Health Centre for Children (SHHC), a leading provincial facility offering specialized services to children and youth with developmental disabilities from birth to age 19, works collaboratively with BCCH. SHHC focuses on the child and their family while supporting health care professionals in their community. BCCH also operates a wide number of specialized health programs, is a leading acute care teaching facility, and conducts research to advance health and care through the BC Children’s Hospital Research Institute and in partnership with the University of British Columbia. BCCH is a leading acute care teaching facility which also operates a wide variety of specialized health and research programs in partnership with BC Children’s Hospital Research Institute and the University of British Columbia.
BCCH is part of the Provincial Health Services Authority (PHSA) which plans, manages and evaluates specialty and province-wide health care services across BC. PHSA embodies values that reflect a commitment to excellence. These include: Respect people • Be compassionate • Dare to innovate • Cultivate partnerships • Serve with purpose
The University of British Columbia (UBC) is Canada’s third largest university and consistently ranks among the 40 best universities in the world. Primarily situated in Vancouver, UBC is a research-intensive university and has an economic impact of $4 billion to the provincial economy.
Dr. Melvin (Mel) Freedman, former Head of the Division of Haematology/Oncology at SickKids, passed away on January 2. He leaves a rich legacy from which his colleagues in Haematology/Oncology continue to benefit. Below, a tribute from the team:
Dr. Melvin Freedman, an iconic international leader in the field of paediatric haematology/oncology since the late 1960s, passed away in his sleep on January 2, 2019 after a long and courageous battle with cancer.
Mel was born and raised in New Brunswick, completed his medical training at McGill University, and his paediatric and haematology residencies in the United States before being recruited to SickKids in 1971, where he spent his entire professional career. Over the years, many institutions from around the world attempted to recruit Mel, but he was passionate about SickKids and never saw the need to move elsewhere.
Mel’s career spanned a remarkable revolution in childhood cancer care. He witnessed the initial uses of chemotherapy to treat a variety of childhood cancers and cared for many of the first children with leukemia who were actually long-term survivors of their disease. Toward the close of his career, he saw the emergence of molecular and genomic technologies being applied to the practice of paediatric oncology and haematology.
In addition to being a compassionate, caring and dedicated doctor to his young patients and their parents, Mel was a brilliant, productive scientist whose work expanded our understanding of haematopoiesis, leukemia stem cell biology, development of rational approaches to leukemia clinical trial design and innovative management of haemoglobinopathies, including allogeneic stem cell transplantation. Mel also pioneered research and treatment of congenital neutropenia and other inherited bone marrow failure syndromes.
Mel’s legacy is measured not only in the thousands of children who benefited from his care and research, but also the innumerable students, residents, junior faculty, nurses and all allied health-care colleagues who he mentored with wisdom, kindness and patience – who went on to build their own careers around the world. Mel was an inspiring teacher, who showed his students the value of asking cutting questions and had the gift of real wit that could level any pretense.
Among the many accolades recognizing his many contributions, one that resonates particularly is the Medical Staff Association Citizenship Award in 2012 — a testament to a truly renaissance man who selflessly gave so much to his colleagues, his patients and our institution.
He was a greatly admired leader both here and at the University of Toronto in many capacities, including Head of the Division of Hematology/Oncology in the 1990s, Chair of the SickKids Research Ethics Board and Head of the Department of Pediatrics Academic Promotions Committee. In each of these roles, he was respected at all levels of governance and admired by all who came to know him. Even since his retirement and during his illness, Mel continued to enjoy hearing stories about and taking great pride in the successes of his colleagues and friends.
Mel leaves behind his wife Lila, his children Monica and Jamie, and many grandchildren. His passing leaves a great hole in the hearts of all who knew him in their academic or personal lives. At the same time, we know that our lives are much the richer for having had the honour to have been in his company.
REGISTRATION NOW OPEN for the C17 Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology workshop (04-Nov- 2017, pre-session meeting at CCRA conference in Vancouver)
C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop will be held on Saturday, 4 November 2017 in Vancouver, BC. The workshop is in response to the C17 DVL needs assessment that was completed last year; members from all C17 DVL sites and PROFYLE clinical site leads are encouraged to attend.
The workshop is a full day, pre-session workshop at the CCRA Canadian Cancer Research Conference. We hope that most attendees at our workshop will take the opportunity to attend the full conference as well.
The workshop will be designed to educate investigators on traditional models of early phase trials as well as newer approaches to drug development. We will also cover regulatory, ethical, advocacy and access aspects of early phase trials. The workshop will proved education, discussions, panels and time for questions.
Travel and accommodation booking information will be emailed to you upon completion of the registration.
CAN YOU RECOGNIZE THE SYMPTOMS OF THE DICER1 SYNDROME? New DICER1 online resource physicians and patients, including variant maps, biobanking instructions and genetic testing. www.dicer1syndrome.ca
With over 50 years of combined research experience, clinician-researchers Dr. William Foulkes and Dr. David Malkin, are pleased to introduce a new resource for patients and healthcare professionals interested in learning more about DICER1 syndrome. Until now, our research has contributed to allowing caregivers recognize the major features of the syndrome, counsel families about the mutation status in their families, and offer surveillance for certain conditions that can occur in those carrying DICER1 mutations. However, due to the rarity of DICER1 syndrome and related tumors, the study of DICER1 syndrome has been limited by the number of cases which occur. This Canadian research network will work to provide an international resource for the dissemination of the information that has been learned about DICER1 syndrome (available in English, French, and Spanish), a DICER1 sample database available for researchers at no cost, and a tool for broadening our reach for case and specimen collection. Please visit our website (www.dicer1syndrome.ca) or contact Evan Weber (firstname.lastname@example.org) for more information.
KTE-C19 now open: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia. For more information see: https://clinicaltrials.gov/ct2/show/NCT02625480
The May 2017 NAIT newsletter can be found HERE. For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to email@example.com
Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung
BOOKMARK NAIT: The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html
HELPING FAMILIES NAVIGATE: To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.
The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.
- Knowledge to Action grants (abstract registration deadline April 1; funding start November 1, 2017)
- Impact grants (letter of intent deadline April 3; funding start February 1, 2018)
- Innovation grants with a focus only on prevention (abstract registration deadline May 1; funding start November 1, 2017)
- Quality of Life grants (letter of intent deadline May 15; funding start February 1, 2018)
Visit the CCSRI website for information: www.cancer.ca/research
BioCanRx invites researchers and their teams to participate in its open, rolling research funding call. The open call builds on past and ongoing investments in the area of cancer biotherapeutics and aims to strengthen Canada’s ability to develop this emerging and promising area of cancer research.